Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 428-310-5 | CAS number: 225789-38-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- August- September 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Objective of study:
- absorption
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The solubility and availability for absorption through the gut wall (bioaccessibility) of the Phosphorus and Aluminium component of the test substance are determined in a model system that simulates the dynamic conditions in the gastro-intestinal tract (TIM-1).
- GLP compliance:
- no
- Remarks:
- not applicable for this study type; the model has been validated for use in the food/nutrition and pharmaceutical area
- Radiolabelling:
- no
- Species:
- other: n.a., in vitro study
- Details on test animals or test system and environmental conditions:
- Please refer to "Details on study design"
- Route of administration:
- other: n.a., in vitro study
- Vehicle:
- other: water/artificial saliva
- Details on exposure:
- Please refer to "Details on study design"
- Duration and frequency of treatment / exposure:
- 300 min.
- Remarks:
- Doses / Concentrations:
9 g substance in artificial saliva and water - No. of animals per sex per dose / concentration:
- n.a., TIM model used
- Control animals:
- other: n.a.
- Positive control reference chemical:
- n.a.
- Details on study design:
- Test system: TIM-1
The TIM-1 system consists of one gastric compartment and three small intestinal compartments maintained at body temperature (please refer to attached document 1 "scheme of TIM model"). The stomach compartment mixing takes place of the ingested contents with secreted gastric acid, enzymes (lipase, amylase and pepsin) and electrolytes (0.5 mL/min.). It is connected to the duodenum compartment by awalve simulating the pyloric sphincter ("scheme of TIM model", B) that gradually transfers chyme (meal and drug product) from stomach into the duodenum compartment. Within the duodenum the pH is increased by bicarbonate secretion. The digestion, solubilisation and release processes are continued under continuous mixing and by secretion of bile and pancreatic juice containing all relevant enzyme (1 mL/min.). After a short residence time the chyme is transported to the jejunum compartment where it is exposed to a higher pH. In this compartment the bile salt concentration is decreased by removal of the bile salts. Digested components, dissolved drug and other low molecular weight compounds are removed by a specific membrane system from the lumen through dialysis (10 mL/min., "scheme of TIM model", M). The same processes take place in the ileum compartment under a slightly elevated pH level. The undigested and un-dissolved compounds were emptied from the ileum compartment according an exponential curve with halftime of 150 min. and collected in a vessel. This ileum efflux is regarded as material that enters the large intestine in vivo ("scheme of TIM model", H). - Details on dosing and sampling:
- please refer to "Any other information"
- Statistics:
- None
- Preliminary studies:
- none
- Type:
- absorption
- Results:
- 0.1% of the administered Al amount corresponding to 0.008% of the complete substance dose
- Type:
- absorption
- Results:
- 26.6% of the administered P amount
- Details on absorption:
- Please refer to "any other information on results incl. tables"
- Details on distribution in tissues:
- n.a.
- Details on excretion:
- n.a.
- Metabolites identified:
- no
- Conclusions:
- The bioaccessibility of aluminium and phosphorus under the conditions of the TIM model (fasted adult human) was determined to be 0.1% and 26.3% of the administered aluminium and phosphorus dose, respectively.
- Executive summary:
The solubility and availability for absorption through the gut wall (bioaccessibility) of the Phosphorus and Aluminium component of the test substance are determined in a model system that simulates the dynamic conditions in the gastro-intestinal tract (TIM-1).
Dynamic gastrointestinal model, TIM-1
The TNO in vitro gastrointestinal models simulate in high degree the successive dynamic processes in the stomach and the small intestine (TIM-1 system). This system is a unique tool to study the stability, release, dissolution, absorbtion and bioconversion of nutrients, chemicals, bioactive compounds and pharmaceuticals in the gastrointestinal (GI) tract. The model has been validated for the simulation of physiological conditions within the lumen of the GI tract in the food and nutrition area as well as in the pharmaceutical area. The results obtained in the TIM system showed very good resemblance with the results obtained in studies with humans and animals for drugs and formulations.
Conclusion
The endogenous intake of aluminium and phosphorus was negligible compared to the doses coming from the substance. Bioaccessible aluminium and phosphorus from the endogenous intake were 0 mg and 11.2 mg, respectively. After administration of 678.4 mg aluminium from the substance, 0.1% of the administered aluminium dose (0.7 mg aluminium and corresponding to 0.008% of the complete substance dose) was bioaccessible, 50.6% was emptied from the ileum compartment and 47.4% was retained in the compartments of the TIM-system. as non-bioaccessible fractions. For phosphorus, the bioaccessible fraction from a 2344 mg dose was 26.3% (617.8 mg). From this dose was 39.0% emptied from the ilem and 39.2% was recovered from the compartments at the end of the experiment. These fractions can be regarded as non-bioaccessible.
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- September 1998
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Abstract only (restricted reporting)
- Objective of study:
- excretion
- toxicokinetics
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Deviations:
- yes
- Remarks:
- 2 animals/dose group, epired air not examined, uncomplete recovery
- GLP compliance:
- no
- Radiolabelling:
- no
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- No details stated
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- The test substance was applied once in the morning.
- Duration and frequency of treatment / exposure:
- single application
- Dose / conc.:
- 180 mg/kg bw (total dose)
- Dose / conc.:
- 1 000 mg/kg bw (total dose)
- No. of animals per sex per dose / concentration:
- 2 males/dose
- Control animals:
- no
- Positive control reference chemical:
- None
- Details on study design:
- None
- Details on dosing and sampling:
- After application of the test substance the animals were housed in metabolism cages and urine and feces samples were collected every 12 h for 72 h in total.
- Statistics:
- n.a.
- Type:
- excretion
- Results:
- only a small amount of the applied dose (10.5 - 13.6%) was excreted via urine, the majority of the recovered test substance was excreted via feces (41.1 - 48.2%)
- Details on absorption:
- Due to the poor water/oil solubility of the test substance only small amounts of the applied doses were absorbed by the gastro-intestinal tract and excreted via urine. The major amount was found in the feces (unabsorbed fraction).
- Details on excretion:
- After application of the test substance only small amounts (10.5 +/- 1.2% after application of 180 mg/kg bw, 13.6 +/- 1.5% after application of 1000 mg/kg bw) of the free phosphinic acid was found in the urine. 31P analysis showed only signals of the free phosphinic acid.
The highest amount of test substance (48.2 +/- 3.8% after application of 180 mg/kg bw, 41.1 +/- 2.4% after application of 1000 mg/kg bw) was found in the feces. After 36h no more test substance was detected. - Metabolites identified:
- yes
- Details on metabolites:
- Only the free phosphinic acid was detected in the urine.
- Conclusions:
- Only a small amount of the applied dose (10.5 - 13.6%) was excreted via urine, the majority of the recovered test substance was excreted via feces (41.1 - 48.2%)
- Executive summary:
The test substance was applied to male rats (180 and 1000 mg/kg bw) by gavage (single application).
After application of the test substance the animals were housed in metabolism cages and urine and feces samples were collected every 12 h for 72 h in total. Due to the poor water/oil solubility of the test substance only small amounts of the applied doses were absorbed by the gastro-intestinal tract and excreted via urine. The major amount was found in the feces (unabsorbed fraction). After application of the test substance only small amounts (10.5 +/- 1.2% after application of 180 mg/kg bw, 13.6 +/- 1.5% after application of 1000 mg/kg bw) of the free phosphinic acid was found in the urine. 31P analysis showed only signals of the free phosphinic acid. The highest amount of test substance (48.2 +/- 3.8% after application of 180 mg/kg bw, 41.1 +/- 2.4% after application of 1000 mg/kg bw) was found in the feces. After 36h no more test substance was detected.
Referenceopen allclose all
Intake
The endogenous intake of aluminium originating from the total secreted gastric electrolyte solution (incl. enzymes), pancreatic juice, bile and small intestinal electrolyte solutions was approx. 0.1 mg (0.066 mg). The endogenous intake of phosphorus was 18 mg. The content of aluminium and phosphorus in the substance was determined on the basis of 75.4 g aluminium/ kg substance and 260.5 g phosphorus/kg substance, respectively. These concentrations were used to calculate the intake of aluminium and phosphorus in the TIM system from a 9 gram dose of the substance.
Aluminium and phosphorus intake in the control experiment and from administered dose testsubstance:
|
|
Amount (mg) |
|
|
|
Endogenous intake |
Al P |
0.1 18.1 |
|
|
|
Dose from Testsubstance |
Al P |
678.4 2344.6 |
|
|
|
The endogenous intake of aluminium and phosphorus was negligible compared to the doses coming from the testsubstance.
Recovery
Experiments were performed successfully with good recoveries for aluminium and phosphorus. After administration of 678.4 mg aluminium from the testsubstance, 98.1 mg of the administered amount was recovered from all samples. The recovery of the administered dose of 2344 mg phosphorus was 104.5%.
Only in the control experiment a recovery below 90% was determined for aluminium; possibly due to the sample concentrations around and below the detection level (LOQ and LOD) of the analytical method.
Bioaccessibility from endogenous intake
Aluminium sample concentrations from the dialysate fractions in the control experiment were below the LOD. Thus, no bioaccessible aluminium was determined.
For phosphorus approx. 11 mg became bioaccessible from endogenous intake. A baseline was generated and used to correct the results from the testsubstance experiment.
Bioaccessibility from the testsubstance, please refer to attached document ("Document 3_Bioaccessibility of aluminium and phosphorus")
The absolute (mg) and relative (% of dose administered) (cumulative) bioaccessible fractions of aluminium and phosphorus from the testsubstance have been corrected for the endogenous contribution of phosphorus. No correction for the endogenous contribution of aluminium was required.
After administration of 678.4 mg aluminium from the testsubstance, 0.1% of the administered dose (0.7 mg) was bioaccessible, 50.6% was emptied from the ileum compartment and 47.4% was retained in the compartments of the TIM-system as non-bioaccessible fractions. For phosphorus the bioaccessible fraction from a 2344 mg dose was 26.3% (617.8 mg). From this dose was 39.0% emptied from the ileum and 39.2% was recovered from the compartments at the end of the experiment. These fractions can be regarded as non-bioaccessible.
Table: Aluminium and phosphorus recovered from TIM from the endogenous intake (0.1 mg and 18.1 mg) and from the administered dose of testsubstance (678.1 mg and 2344.7 mg).
|
|
Control (% of endogenous intake) |
DEPAL (% of dose testsubstance) |
||
|
|
Aluminium |
Phosphorus |
Aluminium |
Phosphorus |
Total bioaccessibility* |
|
0.0 |
62.1 |
0.1 |
26.3 |
Ileum efflux |
|
5.8 |
5.2 |
50.6 |
39.0 |
Residues** |
|
29.7 |
23.2 |
47.4 |
39.2 |
Total recovery |
|
35.5 |
90.5 |
98.1 |
104.5 |
|
|
|
|
|
|
* Bioaccessibility |
|
|
|
|
|
Jejunum |
|
0.0 |
50.6 |
0.0 |
12.5 |
Ileum |
|
0.0 |
11.5 |
0.1 |
13.8 |
|
|
|
|
|
|
** residues + rinse |
|
|
|
|
|
Stomach compartment |
|
0.0 |
0.3 |
23.8 |
23.9 |
Duodenum compartment |
|
0.0 |
9.9 |
2.8 |
2.8 |
Jejunum compartment |
|
29.7 |
8.8 |
9.3 |
6.5 |
Ileum compartment |
|
0.0 |
4.2 |
11.5 |
5.9 |
The ileum compartment showed a higher dialysed amount compared to the jejunum from the substance. The circumstances of the ileum (higher pH value compared to jejunum) and the prolonged exposure time to GI luminal conditions may enhanced the dissolution process of phosphorus and aluminium.
Description of key information
The registration substance is of very low bioavailability.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Toxicokinetics:
An in vitro bioaccessibility study and an in vivo toxicokinetic/excretion estimation were conducted with the test item.
- The solubility and availability for absorption through the gut wall (bioaccessibility) of the test substance was determined in a model system that simulates the dynamic conditions in the gastro-intestinal tract of a fasted healthy human adult (TIM-1):
The endogenous intake of aluminium and phosphorus was negligible compared to the doses coming from the substance. Bioaccessible aluminium and phosphorus from the endogenous intake were 0 mg and 11.2 mg, respectively. After administration of 678.4 mg aluminium from the substance, 0.1% of the administered aluminium dose (0.7 mg aluminium and corresponding to 0.008% of the complete substance dose) was bioaccessible, 50.6% was emptied from the ileum compartment and 47.4% was retained in the compartments of the TIM-system. as non-bioaccessible fractions. For phosphorus, the bioaccessible fraction from a 2344 mg dose was 26.3% (617.8 mg). From this dose was 39.0% emptied from the ilem and 39.2% was recovered from the compartments at the end of the experiment. These fractions can be regarded as non-bioaccessible.
- The test substance was applied to male rats (180 and 1000 mg/kg bw) by gavage (single application).
After application of the test substance the animals were housed in metabolism cages and urine and feces samples were collected every 12 h for 72 h in total. Only small amounts of the applied doses were absorbed by the gastro-intestinal tract and excreted via urine. The major amount was found in the feces (unabsorbed fraction). After application of the test substance only small amounts (10.5 +/- 1.2% after application of 180 mg/kg bw, 13.6 +/- 1.5% after application of 1000 mg/kg bw) of the free phosphinic acid was found in the urine. 31P analysis showed only signals of the free phosphinic acid. The highest amount of test substance (48.2 +/- 3.8% after application of 180 mg/kg bw, 41.1 +/- 2.4% after application of 1000 mg/kg bw) was found in the feces. After 36h no more test substance was detected.
Discussion on bioaccumulation potential result:
- The registration substance is of very low bioavailability, as evidenced by the results obtained from the kinetic studies. Consequently, it is of no bioaccumulating.
- In the available short and long-term studies no effects were seen up to the highest dose level, supporting the very low bioavailability and no bioaccumulating property.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.